SII defended the price of the Covid vaccine and said the initial price was based on advance funding. “There is an inaccurate comparison between the India vaccine price and global prices,” SII said.
New Delhi. in country COVID-19 India’s most used vaccine maker Serum Institute Of India, on Saturday defended the decision to fix the price of the Covishield vaccine one-and-a-half times the initial price, saying the initial price was based on upfront financing and now needs to invest more to increase production capacity. The Pune-based Serum Institute of India (SII) had earlier this week fixed the vaccine price at Rs 400 per dose for a new agreement with state governments and the central government and Rs 600 per dose for private hospitals. SII manufactures AstraZeneca’s Vaccine Covishield. It is currently supplying the vaccine at the rate of Rs 150 per dose to the central government. SII said, “There has been an inaccurate comparison between the price of the India vaccine and the global prices.”
Covishield is the cheapest Kovid-19 vaccine available on the market today. “The company said the initial price was” low worldwide, as it was based on advance funding from countries that included the risk of vaccine manufacture. “The initial price of Covishield was the lowest for all government immunization programs, including India,” the company said. The company added, “The current situation is completely different, the virus is constantly changing, while on the public.” The risk remains. Identifying the uncertainty, we have to ensure stability, as we have to invest in capacity expansion to fight the epidemic and save lives. ”SII said a small portion of the vaccine should be given to private hospitals for Rs 600 per Will be sold at a dose rate and this price is still lower than many other medical treatments.